

200704PPP Proof of Principle Program

Canada

Updated: 25/06/2007

Results of the: 02/04/2007

Name(s) Institution Paid Research Institution * Title	CIHR Contribution	Partner	Partner(s) Contribution	Term	Status
ANDRYSEK, Jan Bloorview Kids Rehab (Toronto) Development and clinical testing of a low-cost prosthetic knee joint	\$ 129,510			1 Yr(s)	
AUCLAIR, Karine McGill University Inhibitors of aminoglycoside acetyltransferases as agents to block resistance to aminoglycoside antibiotics	\$ 150,000			1 Yr(s)	
CHEMTOB, Sylvain Hôpital Sainte-Justine (Montréal) Development of a selective interleukin-23 receptor antagonist for the treatment of inflammatory autoimmune diseases.	\$ 150,000			1 Yr(s)	
CRANDALL, Ian E University Health Network (Toronto) Commercialization of Novel Antimalarials	\$ 150,000			1 Yr(s)	
DE BOLD, Adolfo J University of Ottawa University of Ottawa Heart Institute Development of a Long Acting ANF Analogue	\$ 145,360			1 Yr(s)	
EAVES, Connie J University of British Columbia B.C. Cancer Research Centre (Vancouver) Novel Agents to Enhance Engraftment of Proliferating Hematopoietic Stem Cells	\$ 150,000			1 Yr(s)	
FENSTER, Aaron Robarts Research Institute (London, Ont.) 3D Ultrasound scanner system for carotid atherosclerosis	\$ 144,955			1 Yr(s)	

* "Research Institution" is displayed only when it is different from "Institution Paid".



Canada

Name(s) Institution Paid Research Institution * Title	CIHR Contribution	Partner	Partner(s) Contribution	Term	Status
FOSTER, F. S Sunnybrook Health Sciences Centre Forward-Looking Intravascular Volumetric Imaging by Acoustic and Optical Means	\$ 150,000	·		1 Yr(s)	
GALIPEAU, Jacques Sir Mortimer B. Davis Jewish General Hospital-Mtl Lady Davis Institute for Medical Research (Mtl) The Ex Vivo Generation of Suppressive Cells For The Treatment of Multiple Sclerosis	\$ 150,000			1 Yr(s)	
JOHNSTON, Michael R University Health Network (Toronto) Controlled trans-lymphatic delivery of chemotherapeutic agents for treating lymphatic metastasis in lung cancer	\$ 150,000			1 Yr(s)	
KORNELUK, Robert G Children's Hospital of Eastern Ontario (Ottawa) Development of a novel class of apoptosis inducing compounds	\$ 149,870			1 Yr(s)	
KOTRA, Lakshmi P FISH, Eleanor N WITHER, Joan E University Health Network (Toronto) Interferon mimetics as anti-SLE agents	\$ 150,000			1 Yr(s)	
LABUDA, Damian KRAJINOVIC, Maja GORSKA-FLIPOT, Isabelle Hôpital Sainte-Justine (Montréal) Optimization and validation of human papilloma virus probes obtained through in vitro molecular evolution	\$ 150,000			1 Yr(s)	
LEMAIRE, Edward D Ottawa Health Research Institute Ottawa Hospital General Campus (Ottawa Ontario) Biomechanical Stance-Control Knee Ankle Foot Orthosis	\$ 137,727			1 Yr(s)	

* "Research Institution" is displayed only when it is different from "Institution Paid".

*

Canada	i
--------	---

Name(s) Institution Paid Research Institution * Title	CIHR Contribution	Partner	Partner(s) Contribution	Term	Status
LING, Victor University of British Columbia B.C. Cancer Research Centre (Vancouver) Evaluation of novel bile acids to promote bile flow and prevent liver toxicity	\$ 150,000			1 Yr(s)	
MCPHERSON, Peter S McGill University Montreal Neurological Institute A novel, low cost approach for high affinity antibody production	\$ 150,000			1 Yr(s)	
MINCHINTON, Andrew I University of British Columbia B.C. Cancer Research Centre (Vancouver) DEVELOPMENT OF A HYPOXIA ACTIVATED DNA REPAIR INHIBITOR FOR THE TREATMENT OF CANCER	\$ 150,000			1 Yr(s)	
RADZIOCH, Danuta McGill University Fenretinide - a novel therapy for lung disease and osteoporosis associated with Cystic fibrosis	\$ 144,844			1 Yr(s)	
SCHRADER, John W University of British Columbia Optimization of a novel therapeutic for rheumatoid arthritis	\$ 150,000			1 Yr(s)	
SNYDER, Floyd F University of Calgary Genomics based design of antiparasitics: Suicide activation of purine nucleoside analogs by endogenous pathways of bacterial and protozoan pathogens	\$ 150,000			1 Yr(s)	
TSILFIDIS, Catherine Ottawa Health Research Institute Strategies for the rapid upregulation of the X-linked inhibitor of apoptosis (XIAP) for the treatment of retinal detachment and retinal ischemia	\$ 150,000			1 Yr(s)	
WIEBE, Leonard I University of Alberta Radiosensitizers and Hypoxia Diagnostics that Exploit Hypoxia-upregulated Expression of GLUT Transporters	\$ 149,982			1 Yr(s)	

* "Research Institution" is displayed only when it is different from "Institution Paid".